Checkpoint Capital L.P. Grows Stake in Corcept Therapeutics Incorporated $CORT

Checkpoint Capital L.P. increased its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 14.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 392,331 shares of the biotechnology company’s stock after purchasing an additional 48,414 shares during the period. Corcept Therapeutics accounts for 10.9% of Checkpoint Capital L.P.’s portfolio, making the stock its 3rd biggest position. Checkpoint Capital L.P.’s holdings in Corcept Therapeutics were worth $32,607,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. AQR Capital Management LLC lifted its position in Corcept Therapeutics by 546.9% during the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after buying an additional 1,274,215 shares during the period. Norges Bank purchased a new stake in shares of Corcept Therapeutics in the 2nd quarter worth about $72,048,000. TD Asset Management Inc grew its position in shares of Corcept Therapeutics by 16.6% in the 3rd quarter. TD Asset Management Inc now owns 956,136 shares of the biotechnology company’s stock worth $79,464,000 after buying an additional 136,254 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Corcept Therapeutics by 223.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock worth $70,632,000 after acquiring an additional 587,053 shares in the last quarter. Finally, Epoch Investment Partners Inc. increased its stake in shares of Corcept Therapeutics by 10.7% in the 3rd quarter. Epoch Investment Partners Inc. now owns 847,104 shares of the biotechnology company’s stock worth $70,403,000 after acquiring an additional 81,700 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Wall Street Analysts Forecast Growth

CORT has been the topic of several research reports. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a research note on Wednesday, December 31st. Canaccord Genuity Group raised their target price on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Truist Financial set a $50.00 target price on shares of Corcept Therapeutics in a report on Wednesday, December 31st. Zacks Research downgraded Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Finally, UBS Group began coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $77.17.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: H.C. Wainwright cut Corcept’s price target from $67 to $60 but maintained a Buy rating — a partial positive as the analyst still endorses upside despite weaker guidance/earnings. H.C. Wainwright Cuts Price Target
• Neutral Sentiment: Reported short‑interest data in the filings appears unreliable (shows 0 shares / NaN changes); no actionable signal from that report as published. (Data likely erroneous; treat cautiously.)
• Negative Sentiment: Multiple shareholder‑rights firms have filed or issued investor alerts about a newly filed securities class action against Corcept and certain officers, urging investors to seek lead‑plaintiff status (April 21, 2026 deadline). These notices increase headline risk and could pressure the stock as legal exposure and potential discovery unfold. Links: Bronstein Gewirtz Grossman alert. Bronstein Gewirtz Grossman Hagens Berman alerts (two notices). Hagens Berman (GlobeNewswire) Hagens Berman (PRNewswire) Pomerantz, Rosen (multiple notices), Bernstein Liebhard, Schall, DJS Law Group, and Johnson Fistel have also issued alerts or are investigating. Pomerantz Rosen Schall DJS Law Group Bernstein Liebhard
• Negative Sentiment: Hagens Berman’s notices specifically reference an FDA rejection and a federal court patent loss as part of the factual basis for the securities claims — these alleged regulatory and IP setbacks are material if confirmed and could directly affect revenue and exclusivity assumptions. Investors should monitor official FDA/patent filings and company disclosures for confirmation. Hagens Berman: FDA rejection & patent loss

Insider Buying and Selling at Corcept Therapeutics

In related news, insider William Guyer sold 8,233 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $35.99, for a total transaction of $296,305.67. Following the completion of the sale, the insider owned 2,231 shares of the company’s stock, valued at $80,293.69. This trade represents a 78.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 48,233 shares of company stock worth $1,817,306 over the last ninety days. 20.80% of the stock is owned by company insiders.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $32.15 on Friday. The company has a market capitalization of $3.42 billion, a price-to-earnings ratio of 39.21 and a beta of 0.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. Corcept Therapeutics Incorporated has a one year low of $28.66 and a one year high of $117.33. The company’s 50-day moving average is $37.75 and its 200 day moving average is $63.14.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). The firm had revenue of $202.13 million during the quarter, compared to analysts’ expectations of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The firm’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the firm posted $0.26 earnings per share. Sell-side analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.